Eton PharmaceutcialsETON
ETON
About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Employees: 30
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
18,156% more call options, than puts
Call options by funds: $1.64M | Put options by funds: $9K
85% more capital invested
Capital invested by funds: $30.8M [Q2] → $57M (+$26.2M) [Q3]
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
7% more funds holding
Funds holding: 44 [Q2] → 47 (+3) [Q3]
0.33% more ownership
Funds ownership: 36.47% [Q2] → 36.8% (+0.33%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
11%
upside
Avg. target
$18.67
22%
upside
High target
$21
38%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Madison El-Saadi 75% 1-year accuracy 3 / 4 met price target | 38%upside $21 | Buy Initiated | 10 Jan 2025 |
Craig-Hallum Chase Knickerbocker 48% 1-year accuracy 12 / 25 met price target | 18%upside $18 | Buy Maintained | 8 Jan 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 58 / 186 met price target | 11%upside $17 | Buy Maintained | 6 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate).
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purchase of Increlex® (mecasermin injection) from Ipsen S.A. (“Ipsen”). Increlex® is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD).
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO).
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired the U.S. rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus from AMMTeK.
Positive
Zacks Investment Research
2 months ago
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Neutral
Seeking Alpha
2 months ago
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Neutral
GlobeNewsWire
2 months ago
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2024.
Neutral
GlobeNewsWire
2 months ago
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Neutral
GlobeNewsWire
3 months ago
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Neutral
GlobeNewsWire
5 months ago
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
Charts implemented using Lightweight Charts™